Michigan Department of Health and Human Services (MDHHS) Perinatal Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, and Syphilis Testing and Reporting Guidelines

For prenatal care (PNC), labor and delivery (L&D), and emergency department (ED) medical providers.

Physicians and other health care professionals providing medical treatment to birthing people are required, at the time of initial prenatal screening and examination, and during the third trimester, and at delivery in absence of previous testing results to test for HIV, Hepatitis B, Hepatitis C, and Syphilis, unless the birthing person refuses to be tested or the provider deems the tests are medically inadvisable. (Per section 333.5123 of Michigan's Public Health Code, Act No. 368 of the Public Acts of 1978. Amended 12/2018).

Health care facilities should have written policies and procedures, as well as standing orders in place to ensure that HIV, Hepatitis B, Hepatitis C, and Syphilis testing are components of a health care facility's clinical pathways.

A separate consent form for an HIV test is not required. A test subject or his or her authorized representative who provides general informed consent for medical care is considered to have consented to an HIV test. Medical providers must document any declination of testing in the patient's medical record (per section 333.5133 of Michigan's Public Health Code, Act No. 368 of the Public Acts of 1978. Amended 2018).

A physician who orders a test or a health facility that performs a test shall provide accurate testing information to the test subject both before and after the test

is administered.						
PRENATAL, L&D, ED TESTING	HIV	HEPATITIS B	SYPHILIS	HEPATITIS C		
All birthing people in first rimester of pregnancy: All birthing people in third rimester of pregnancy:	 Should be tested for Hepatitis B surface antigen (HBsAg), HIV (4th generation Ag/Ab assay), Hepatitis C antibody, and Syphilis (treponemal and nontreponemal tests), as soon as possible in the first trimester of pregnancy, as part of routine prenatal care. (e.g., upon diagnosis of pregnancy at any healthcare facility; at the initial prenatal visit). All positive screening tests must be confirmed. Consult an infectious disease specialist, or experienced perinatal provider, promptly upon confirmation of a positive test result. Test in the third trimester, and per MDHHS recommendations, between 28-32 weeks, regardless of perceived risk and/or previous negative test result. MDHHS recommends that testing is performed as early in the third trimester (28 weeks) as possible to allow for adequate treatment and best outcomes for the infant. All positive screening tests must be confirmed. Consult an infectious disease specialist, or experienced perinatal provider, promptly upon confirmation of a positive test result. Consult an infectious disease specialist, or experienced perinatal provider, promptly upon confirmation of a positive test result. Consult a pediatric infectious disease specialist upon confirmation of HIV infection in a birthing person so that a care plan for the infant can be developed prior to the onset of labor. CDC.gov/pregnancy-hiv-std-tb-hepatitis/php/screening 					
 Birthing people who are at high risk for nfection: For example, birthing people who: Have a sexually transmitted infection (STI) during pregnancy. Inject drugs or share drug equipment. Have a sex partner who injects drugs. Have a partner who has sexual contact with a man. Exchange sex for money or drugs. Have an HIV-infected partner. Have an HBsAg-positive household member or sex partner. Have a new partner, or more than one sex partner, during the pregnancy. 	Test at any time and as often as necessary regardless of previous negative test results. Test upon admission for delivery regardless of previous negative test results. Test birthing people who have signs or symptoms consistent with acute HIV infection using a plasma RNAtest in conjunction with an HIV antibody test. Consult an infectious disease specialist, or experienced perinatal provider, promptly upon confirmation of a positive test result. Consult a pediatric infectious disease specialist upon confirmation of HIV infection in a birthing person so that a care plan for the infant can be developed prior to the onset of labor.					
 No/late prenatal care, ncomplete screening, or ongoing risk factors such as: Have no record of HBsAg testing. Have no record of Hepatitis C Antibody testing. Have no record of 3rd trimester HIV or Syphilis test result. Have no prenatal care. Present in the immediate postpartum period (24 hours). 	Test STAT with rapid or expedited point of care testing. Every birthing person's medical record should include documentation of testing or declination of testing and reason for refusal. All positive screening tests should be reviewed and confirmed promptly with an infectious disease specialist or HIV experienced perinatal provider. A pediatric infectious disease specialist should be notified about the birthing person's treatment history and viral load so that a care plan can be initiated prior to delivery. All positive screening tests must be confirmed. Hospitals must have procedures in place to report the confirmatory test results and HIV infection status to all birthing people they test. A pediatric infectious disease specialist and MDHHS should be notified of any suspected HIV, Syphilis, Hepatitis B, or Hepatitis C infection in a birthing person so that a care plan for the infant can be developed prior to delivery. Contact information for MDHHS can be found at the bottom of this document. No birthing person should leave the hospital unless the maternal serologic status has been documented.					



1 of 2

Michigan Department of Health and Human Services (MDHHS) Perinatal Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, and Syphilis Testing and Reporting Guidelines

For prenatal care (PNC), labor and delivery (L&D), and emergency department (ED) medical providers

For prenatal care	(PNC), labor and delivery (L&D), and	emergency depar	tment (ED) medi	ical providers.	
Maternal Treatment	Prenatal Care Providers: An appropriate antiretroviral treatment plan should be initiated promptly upon consultation with an infectious disease specialist or HIV experienced perinatal provider. L&D and ED: Hospitals must have mechanisms in place to provide immediate initiation of appropriate antiretroviral prophylaxis - antepartum, intrapartum and/or at the onset of delivery - based on any reactive rapid or expedited HIV test result, without awaiting results of a confirmatory test. People with HIV should receive evidence- based, patient-centered counseling to support their decisions on infant feeding. People with HIV who have consistently suppressed viral loads throughout pregnancy should be informed of the risks and benefits of breastfeeding, chest feeding, formula feeding, and the use of pasteurized donor human milk to support their decision making.	Birthing people who are HBsAg- negative but are at high risk of acquiring HBV should be offered the Hepatitis B (hepB) vaccine series. Birthing people who are HBsAg positive, need to be referred to an infectious disease specialist for follow-up and care.	Birthing people who test positive for Syphilis should receive penicillin G in accordance with current CDC STI Treatment Guidelines.	Birthing people who test positive for HCV should be connected to Hepatitis C care so that direct- acting antiviral treatment may begin postpartum and after completion of breastfeeding.	
Infant Treatment	 Rapid HIV testing is recommended for all infants whose biological birthing person has not been tested. Inform the person legally authorized to provide consent for the infant, that rapid HIV testing is recommended for infants whose HIV exposure is unknown. HIV exposed infants should be started on single or multi drug antiretroviral prophylaxis as soon as possible after birth. Preferably within 6-12 hours of delivery. Postnatal infant prophylaxis is recommended, with 6 weeks of antiretroviral medication(s). Hospitals must have mechanisms in place to: Provide ZDV/AZT, as well as nevirapine if indicated, in syrup form to HIV- exposed infants in-house. Ensure that antiretroviral medications in syrup form are available to the infant after discharge. 	All infants should receive hepB vaccine within 24 hours of birth. Infants born to HBsAg-positive birthing people should receive hepB vaccine and Hepatitis B immune globulin (HBIG) within 12 hours of birth, followed by 2-3 more doses of hepB vaccine and post-vaccination serology 3-6 months after series completion. For safely surrendered babies whose birthing person's HBsAg status is unknown, treat as if the birthing person is HBsAg- positive.	No infant should leave the hospital unless the maternal serologic status has been documented. Infants exposed to Syphilis should be evaluated (including a nontreponemal test), as they may need treatment with penicillin G, according to current CDC STI treatment guidelines, immediately after birth.	 Infants born to birthing persons with current (has detectable HCV RNA) or probable (anti-HCV reactive, HCV RNA results are not available) HCV infection should be tested for hepatitis C at 2-6 months of age with an HCV RNA test. If previously not been tested: Infants ages 7-17 months with perinatal exposure to HCV should receive HCV RNA testing. Infants and children ages 18 months or older with perinatal exposure to HCV RNA testing. Infants or older with perinatal exposure to HCV should receive anti-HCV with reflex to HCV RNA testing. HCV antibody testing should only be conducted in children greater than 18 months old, and if positive, should be confirmed with an HCV RNA test. Infants and children with detectable HCV RNA should be managed in consultation with a health care provider with expertise in pediatric hepatitis C management for related screenings, preventive services, interventions, and regular follow-up. Children who test positive should be retested with a NAT for HCV RNA before beginning treatment, which can be started as early as age 3 years. 	
Documentation	Refusal to test, refusal to accept treatment, and a description of any required perinatal tests that were not performed for any reason, <u>must be documented</u> in the birthing person's medical record. All test results and treatment should be recorded in both the birthing person's and the baby's medical records, along with the date of testing, result, or refusal.				
Reporting	People who test positive for HIV , Hepatitis B , Hepatitis C , and/or Syphilis must be reported within 24 hours, of diagnosis or discovery, to the local health department in the county of which the patient resides. Please also call MDHHS at 313-456-1586 . (Per section 333.5111 of Michigan's Public Health Code, Act No. 368 of the Public Acts of 1978, as amended)				

Consultation concerning implementation of these guidelines can be obtained from:

- Michigan HIV and HCV Consultation Program at Henry Ford Health System, urgent questions (24/7): 313-575-0332
- Midwest AIDS Training and Education Center Michigan (provider education for HCV and HIV): 313-408-3483 or matecmichigan.org
- National Perinatal HIV Consultation and Referral Service: 888-448-8765
 - Michigan Department of Health and Human Services (MDHHS) Questions and Reporting
 - o Perinatal HIV: 313-434-4419
 - Congenital Syphilis: 313-316-4680
 - o Perinatal Hepatitis B: 517-242-8319
 - Perinatal Hepatitis C: 517-335-8165
- Minerva Galang, MD Mercy Health Infectious Disease: 616-397-6586
- Rosemary Olivero, MD Helen DeVos Children's Hospital, Grand Rapids: 616-479-0883
- Theodore Jones, MD, FACOG Beaumont Health Maternal/Fetal Medicine: 313-503-1873
- Eric McGrath, MD, Wayne State University School of Medicine Department of Pediatrics, Division of Infectious Diseases and Prevention: 313-505-4005

Resources

-

Additional perinatal resources including case report forms and Michigan law requirements for perinatal testing can be found at <u>Michigan.gov/PerinatalHIVSTI</u>.



2 of 2